bimekizumab,adalimumab,secukinumab
ucb pharmaceuticals,abbvie,novartis
['bimekizumab', 'adalimumab', 'axspa']
our final axspa session of #acr22 is the late breakers! we've highlighted two as editor's picks - l14 and l15. make sure to see them for two key studies in #bimekizumab and #seckukinumab vs #adalimumab. starting in 15 minutes.
The CSF is a free educational resource specialising in cytokine signalling and inflammatory disease, providing medical education to clinicians around the globe.